Global Next- Generation Biomanufacturing Market, By Workflow and Product (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing), Application (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Others), End User (Commercial Stage, Preclinical and Development Stage) – Industry Trends and Forecast to 2029
Market Analysis and Size
Artificial intelligence, machine learning, and augmented reality, among other advanced technologies, are used in next-generation biomanufacturing processes. When compared to the first-generation procedure, incorporating these technologies provides seamless, efficient, and high-quality results.
Data Bridge Market Research analyses that the next-generation biomanufacturing market which was USD 20.08 billion in 2021, would rocket up to USD 42.58 billion by 2029, and is expected to undergo a CAGR of 9.85% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Workflow and Product (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing), Application (Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Others), End User (Commercial Stage, Preclinical and Development Stage)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Illumina Inc. (US), Thermo Fischer Scientific Inc. (U.S), Oxford Nanopore Technologies plc (U.K), Agilent Technologies, Inc. (U.S), BGI (China), PerkinElmer Inc. (US), QIAGEN (Germany), Eurofins Scientific (Luxembourg), F. Hoffmann-La Roche Ltd (Switzerland), Takara Bio Inc. (Japan), GENEWIZ, Inc. (U.S), Hamilton Company (U.S), Macrogen Inc. (South Korea), Zymo Research Corporation(U.S), Tecan Trading AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
The rapid growth of the biopharmaceutical industry reflects the increasing relevance of biomanufacturing as the primary technique for the development and production of biological-based products, a market known as next-generation biomanufacturing.
Next-Generation Biomanufacturing Market Dynamics
Drivers
- Adoption of advanced technology, and new innovation
Growth of the global biopharmaceutical sector, increased commercialization and pipeline development, adoption of advanced technology, and new innovation in design, efficiency, performance, and other areas are some of the factors that will likely boost the growth of the next-generation biomanufacturing market in the forecast period of 2020-2027. On the other hand, the availability of money from the government and private organisations for the development of novel technologies will increase the number of chances for the next-generation biomanufacturing market to grow throughout the projection period.
- Rising environmental concerns
The worldwide biomanufacturing market will be fueled by rising environmental concerns, pollution levels, water scarcity, and seamless services in the manufacturing of medication.
Plants that implement next-generation biomanufacturing will also increase demand for market share. Furthermore, the adoption of a single-use product strategy will aid in cost-cutting, product contamination reduction, and increased flexibility, resulting in a desire for next-generation biomanufacturing.
Increase in the number of biopharmaceutical businesses
In the forecast period, the next generation bio-manufacturing market is expected to be driven by an increase in the number of biopharmaceutical businesses around the world. The necessity for enhanced biomanufacturing to meet patient demand is projected to propel the next-generation biomanufacturing industry forward.
Opportunities
The development of a next-generation biomanufacturing process allows for the production of biological medication for the treatment of crucial ailments such as liver and kidney disease, cancer, and diabetes. Furthermore, increasing adoption of single-use products such as single-use bio-reactors and bio containers, as well as increasing financial support from private investors and governments for the development of next-generation biomanufacturing units, are among the major factors driving the global next-generation biomanufacturing market, which is expected to continue over the forecast period.
Restraints/Challenges
Huge capital expenditure, associated unpredictable costs, lack of skilled professionals, operational complexity and compatibility challenges are some of the factors which hinders the market growth.
This next-generation biomanufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the next-generation biomanufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 impact on Next- Generation Biomanufacturing Market
The production of vaccines has become the primary focus of the biomanufacturing businesses as a result of the COVID-19 pandemic. Following the coronavirus pandemic, the development of improved vaccines will have an impact on the biopharmaceutical industry's growth. Scientists and engineers are currently concentrating their efforts on developing next-generation biomanufacturing systems that can create improved vaccines at a low cost. They're also concentrating on the vaccination quantities required to respond to future outbreaks and pandemics.
Recent Development
- In April 2020, Cambryn Biologics in Sarasota, Florida, was bought by Akron Biotech. The facility is a biomanufacturing plant with cutting-edge technology.
- In February 2020, Honeywell International Inc. teamed up with Bigfinite, Inc. to contribute to process automation and controls technologies, using Bigfinite's AI, data analytics, and machine learning platform to help the pharmaceutical and biotech sectors pace medicinal therapies.
Global Next- Generation Biomanufacturing Market Scope
The next-generation biomanufacturing market is segmented on the basis of type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Continuous Upstream Biomanufacturing
- Single-Use Upstream Biomanufacturing
- Downstream Biomanufacturing
Application
- Monoclonal Antibodies
- Hormones
- Vaccines
- Recombinant Proteins
- Others
End-User
- Biopharmaceutical Companies
- Research Institutions
- CMOs/CDMOs
Next- Generation Biomanufacturing Market Regional Analysis/Insights
The next-generation biomanufacturing market is analysed and market size insights and trends are provided by country, type, application and end-user as referenced above.
The countries covered in the next-generation biomanufacturing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the next-generation biomanufacturing market due to the adoption of advanced technology and prevalence of various manufacturing companies in the region.
The growing surge in new capacity installations to meet the increased product demand in developing nations of Asia-Pacific is further expected to boost the next-generation biomanufacturing market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Next- Generation Biomanufacturing Market Share Analysis
The next-generation biomanufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to next-generation biomanufacturing market.
Some of the major players operating in the next-generation biomanufacturing market are:
- Illumina Inc. (U.S)
- Thermo Fischer Scientific Inc. (U.S)
- Oxford Nanopore Technologies plc (U.K)
- Agilent Technologies, Inc. (U.S)
- BGI (China)
- PerkinElmer Inc. (U.S)
- QIAGEN (Germany)
- Eurofins Scientific (Luxembourg)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Takara Bio Inc. (Japan)
- GENEWIZ, Inc. (U.S)
- Hamilton Company (U.S)
- Macrogen Inc. (South Korea)
- Zymo Research Corporation(U.S)
- Tecan Trading AG (Switzerland)
SKU-